INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10534796	
Filing Date		2005-05-12	
First Named Inventor Klimk		co, et al.	
Art Unit		1618	
Examiner Name	Fay,	Zohreh A.	
Attorney Docket Numb	er	2443 US F	

	U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date Name of Patentee of Applicant Relevan				s,Columns,Lines where ant Passages or Relevant es Appear			
	1										
If you wis	h to a	⊔ dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	lite Publication Number Kind Publication Name of Patentee or Applicant Polevant E				nt Passag	Lines where ges or Relev				
	1										
If you wis	h to a	⊔ dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ade	d button	Add		
				FOREIG	ON PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	te Number ³ Code ² i Code ⁴ Date Name of Patentee or Name of Name o			vhere Rel	or Relevant	T5				
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								-			
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T5				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10534796	
Filing Date		2005-05-12	
First Named Inventor	Klimk	co, et al.	
Art Unit		1618	
Examiner Name	Fay,	Zohreh A.	
Attorney Docket Number		2443 US F	

/ZF/	1		DELCOURT, et al., "Associations of Antioxidant Enzymes with Cataract and Age-related Macular Degeneration", Ophthalmology, February 1999, pages 215-221, Vol. 106, No. 2							
/ZF/	2		DE LA PAZ, et al., "Red Blood Cell Antioxidant Enzymes in Age-related Macular Degeneration", British Journal of Ophthalmology, 1996, pages 445-450, Vol. 80							
If you wis	h to a	dd adc	ditional non-patent literature document citation information p	lease click the Add b	outton Add					
			EXAMINER SIGNATURE							
Examiner Signature /Zohreh Fay/ (03/12/2010) Date Considered										
*EXAMIN	ER: Ir	nitial if	reference considered, whether or not citation is in conforma	ance with MPEP 609	. Draw line through a					

¹ See Kind Codes of USPTO Patent Documents at www_USPTO_60\(\frac{1}{2}\) or MPEP 901.04. ² Entire office that issued the accoument, by the two-letter code (NIPO Standard ST.3). ³ For Japanese patent documents, bis indication of the typeror must precode the series in unber of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10534796
Filing Date		2005-05-12
First Named Inventor	Klimk	o, et al.
Art Unit		1618
Examiner Name	Fay,	Zohreh A.
Attorney Docket Number		2443 US F

CERTIFICATION STATEMENT

Please see '	37 CFR 1	97 and 1 98 to	make the annir	nniate selection(s)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1-97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filling of the information disclosure statement, See 37 CFR 1.76(e)2.

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

- NI---

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jason J. Derry, #50,692/	Date (YYYY-MM-DD)	2007-08-01
Name/Print	Jason J. Derry	Registration Number	50,692

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of hext, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.